Increasingly common in daily practice, this is the first guideline update since 2011, aimed to improve success rates and cut complications.
MediWound has commenced a pivotal, multicentre Phase III VALUE trial to assess its bioactive debridement therapy, EscharEx, ...
A Republican senator’s ranted accusation that the U.S. military has lowered its standards due to diversity, equity and inclusion programs was spectacularly undermined by a typo on a poster behind him.